Asunto(s)
Crisis Blástica/patología , Linaje de la Célula , Gránulos Citoplasmáticos/patología , Células Mieloides/patología , Leucemia-Linfoma Linfoblástico de Células Precursoras B/diagnóstico , Enfermedad Aguda , Colorantes Azulados , Citodiagnóstico , Diagnóstico Diferencial , Femenino , Humanos , Persona de Mediana Edad , Leucemia-Linfoma Linfoblástico de Células Precursoras B/genéticaRESUMEN
The responses to sublingual nifedipine (20 mg) and placebo were compared in normal subjects during two studies on cycle ergometer [progressive exercise and constant work-load exercise at approximately 60% of maximal O2 consumption (VO2max)]. The use of nifedipine did not modify maximal power, ventilation (VE), VO2, and heart rate (HR) at the end of the multistage progressive exercise (30-W increments every 3 min). Over the 45 min of the constant-load exercise and the ensuing 30-min recovery we observed with nifedipine compared with placebo 1) no differences in VO2, VE, respiratory exchange ratio, and systolic arterial blood pressure; 2) a higher HR (P less than 0.001) and lower diastolic arterial blood pressure (P less than 0.01); 3) a greater and more prolonged rise in norepinephrine (P less than 0.01) and growth hormone (P less than 0.001); 4) no significant differences in epinephrine and insulin and a lesser increase in glucagon during recovery (P less than 0.01); and 5) a lesser fall in blood glucose (P less than 0.01) and greater increase in acetoacetate (P less than 0.001), beta-hydroxybutyrate (P less than 0.05), and blood lactate (P less than 0.001). Our data do not support the hypothesis that nifedipine reduces hormonal secretions in vivo and are best explained by an enhanced secretion of catecholamines compensating for the primary vasodilator effect of nifedipine.
Asunto(s)
Nifedipino/farmacología , Esfuerzo Físico/efectos de los fármacos , Ácido 3-Hidroxibutírico , Acetoacetatos/sangre , Adulto , Glucemia/metabolismo , Presión Sanguínea/efectos de los fármacos , Ácidos Grasos no Esterificados/sangre , Femenino , Glucagón/sangre , Hormona del Crecimiento/sangre , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Hidroxibutiratos/sangre , Insulina/sangre , Lactatos/sangre , Ácido Láctico , Masculino , Ventilación Voluntaria Máxima , Persona de Mediana Edad , Norepinefrina/sangre , Intercambio Gaseoso Pulmonar/efectos de los fármacos , Piruvatos/sangre , Ácido Pirúvico , Respiración/efectos de los fármacos , Factores de Tiempo , Triglicéridos/sangreRESUMEN
The isoenzymes 1 and 2 (LDH1 and LDH2) of lactic dehydrogenase (LDH) were studied in the serum of 32 patients with malignant haematological diseases. In non-Hodgkin lymphoma (NHL) a diminution in LDH1 and an increase in LDH2 was a sign of evolution towards a more aggressive phase of the disease, or the absence of clinical remission, even when no significant variation of total LDH can be observed in the serum. In acute lymphoblastic leukaemia (ALL), the isoenzymatic variations are not an early indication of relapse. No significant variations in serum LDH or of these isoenzymes was observed in chronic lymphocytic leukaemia (CLL) or Hodgkin's disease (HD). Only in NHL did the variations of LDH1 and LDH2 appear to be a biochemical marker of the tumour process and of cellular differentiation.